Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreUganda National Drug Policy (WHO; 2002; 45 pages)
Afficher le documentForeword
Afficher le documentPreface
Afficher le documentIntroduction
Afficher le documentMembers of the MoH Task Force on Drug Management
Afficher le documentNational Drug Policy
Afficher le document1. Pharmaceutical legislation and regulation
Afficher le document2. Drug selection
ouvrir ce répertoire et afficher son contenu3. Drug supply system (quantification, procurement, storage, distribution)
ouvrir ce répertoire et afficher son contenu4. Rational drug use and drug information
fermer ce répertoire5. Drug financing and pricing
Afficher le document5.1 Drug financing
Afficher le document5.2 Drug pricing
Afficher le document6. Traditional medicines
Afficher le document7. Human resource development
Afficher le document8. Research and development
Afficher le document9. Technical co-operation
Afficher le document10. Monitoring and evaluation
 

5.2 Drug pricing

Goal: to promote equity of access to essential drugs by ensuring that they are affordable to the country and the population

Objectives:

1. To maintain consumer prices of essential medicines available in the country at the minimum possible using all available options.


Strategies:

1. Design, establish and maintain a system for the monitoring of world market, local retail, wholesale and cost prices of essential drugs, setting of indicator prices and the regular and effective dissemination of these to both suppliers and consumers (see also 5.1 strategy 4)

2. Ensure that prices of drugs purchased for the public sector do not exceed the relevant indicator price through close monitoring of procurement at each level

3. Actively promote the concepts and practice of generic prescribing and appropriate generic substitution as a means of minimising drug costs

4. Ensure that the implications of the World Trade Organisation Agreement on Trade-Related Aspects of Intellectual Property Rights (WTO/TRIPS Agreement) are well publicised and understood by the relevant policy-makers.

5. Ensure that national patent legislation is suitably amended to enable advantage to be taken of WTO/TRIPS Agreement exemption provisions related to the importation and manufacture of patented medicines.

6. Ensure appropriate application of the (WTO/TRIPS Agreement) provisions related to the importation and manufacturing of patent medicines (eg. compulsory licences, parallel imports, allowable exceptions).

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires Anglais  |  Français